Addressing adherence challenges in long-term statin treatment among Asian populations: Current gaps and proposed solutions

IF 4.3 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
Elmer Jasper B Llanes , Nuntakorn Thongtang , Zhen-Vin Lee , Tran Hoa , Ong Hean Yee , Renan Sukmawan
{"title":"Addressing adherence challenges in long-term statin treatment among Asian populations: Current gaps and proposed solutions","authors":"Elmer Jasper B Llanes ,&nbsp;Nuntakorn Thongtang ,&nbsp;Zhen-Vin Lee ,&nbsp;Tran Hoa ,&nbsp;Ong Hean Yee ,&nbsp;Renan Sukmawan","doi":"10.1016/j.ajpc.2025.101019","DOIUrl":null,"url":null,"abstract":"<div><div>Statin therapy, known for its lipid-lowering properties, substantially lowers the risk of cardiovascular events in patients vulnerable to atherosclerotic cardiovascular disease (ASCVD) across diverse demographic groups. Despite evidence supporting their benefits, statins are often underutilized or even discontinued. Disparities in statin utilization exist across Asian countries due to healthcare system policies and economic circumstances. Addressing these disparities is essential, especially in the context of global initiatives designed to enhance affordability and raise awareness. Healthcare practitioners (HCPs) must assess ASCVD risks and take proactive measures aimed at lowering these risks, particularly through the management of low-density lipoprotein cholesterol (LDL-C) levels. It is imperative for HCPs and patients to collaborate for effective management of ASCVD risk, prioritizing improved adherence, treatment continuity, and better health outcomes. This review focuses on statin utilization and adherence in six Asian countries—Thailand, Malaysia, Philippines, Vietnam, Singapore, and Indonesia. It aims to explore the common factors that influence long-term adherence to statin treatment and also offers practical recommendations to improve adherence, ultimately leading to better cardiovascular outcomes in the Asian population.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"23 ","pages":"Article 101019"},"PeriodicalIF":4.3000,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of preventive cardiology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666667725000947","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Statin therapy, known for its lipid-lowering properties, substantially lowers the risk of cardiovascular events in patients vulnerable to atherosclerotic cardiovascular disease (ASCVD) across diverse demographic groups. Despite evidence supporting their benefits, statins are often underutilized or even discontinued. Disparities in statin utilization exist across Asian countries due to healthcare system policies and economic circumstances. Addressing these disparities is essential, especially in the context of global initiatives designed to enhance affordability and raise awareness. Healthcare practitioners (HCPs) must assess ASCVD risks and take proactive measures aimed at lowering these risks, particularly through the management of low-density lipoprotein cholesterol (LDL-C) levels. It is imperative for HCPs and patients to collaborate for effective management of ASCVD risk, prioritizing improved adherence, treatment continuity, and better health outcomes. This review focuses on statin utilization and adherence in six Asian countries—Thailand, Malaysia, Philippines, Vietnam, Singapore, and Indonesia. It aims to explore the common factors that influence long-term adherence to statin treatment and also offers practical recommendations to improve adherence, ultimately leading to better cardiovascular outcomes in the Asian population.
解决亚洲人群长期他汀类药物治疗的依从性挑战:目前的差距和建议的解决方案
他汀类药物治疗,以其降脂特性而闻名,大大降低了不同人群易患动脉粥样硬化性心血管疾病(ASCVD)患者心血管事件的风险。尽管有证据支持他汀类药物的益处,但他汀类药物经常未被充分利用,甚至被停用。由于医疗保健制度政策和经济环境,他汀类药物的使用在亚洲国家存在差异。解决这些差异至关重要,特别是在旨在提高负担能力和提高认识的全球举措的背景下。医疗从业者(HCPs)必须评估ASCVD的风险,并采取积极的措施,旨在降低这些风险,特别是通过管理低密度脂蛋白胆固醇(LDL-C)水平。医护人员和患者必须合作有效地管理ASCVD风险,优先考虑改善依从性、治疗连续性和更好的健康结果。本综述的重点是六个亚洲国家——泰国、马来西亚、菲律宾、越南、新加坡和印度尼西亚——他汀类药物的使用和依从性。本研究旨在探讨影响他汀类药物长期依从性的共同因素,并提供切实可行的建议以提高依从性,最终改善亚洲人群的心血管预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
American journal of preventive cardiology
American journal of preventive cardiology Cardiology and Cardiovascular Medicine
CiteScore
6.60
自引率
0.00%
发文量
0
审稿时长
76 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信